MXPA05013233A - Derivados de imidazol heteroaril-substituidos como antagonistas del receptor de glutamato. - Google Patents
Derivados de imidazol heteroaril-substituidos como antagonistas del receptor de glutamato.Info
- Publication number
- MXPA05013233A MXPA05013233A MXPA05013233A MXPA05013233A MXPA05013233A MX PA05013233 A MXPA05013233 A MX PA05013233A MX PA05013233 A MXPA05013233 A MX PA05013233A MX PA05013233 A MXPA05013233 A MX PA05013233A MX PA05013233 A MXPA05013233 A MX PA05013233A
- Authority
- MX
- Mexico
- Prior art keywords
- heteroaryl
- receptor antagonists
- glutamate receptor
- imdazole derivatives
- substituted
- Prior art date
Links
- 239000003825 glutamate receptor antagonist Substances 0.000 title 1
- 208000002193 Pain Diseases 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 150000002460 imidazoles Chemical class 0.000 abstract 2
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 abstract 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
La presente invencion se refiere a derivados de imidazol de la formula general (I) en donde R1, R2, R3 y R4 se definen en la especificacion asi como a sales farmaceuticamente aceptables de los mismos y a procesos de obtencion de los mismos. La invencion se refiere ademas al uso de dichos derivados de imidazol para la fabricacion de medicamentos y a medicamentos que los contienen para la prevencion o el tratamiento de trastornos mediados por el receptor de mGluR5, por ejemplo los trastornos neurologicos agudos y/o cronicos, en particular la ansiedad, o para el tratamiento del dolor agudo y cronico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03012290 | 2003-06-12 | ||
| PCT/EP2004/006111 WO2004111040A1 (en) | 2003-06-12 | 2004-06-07 | Heteroaryl-substituted imdazole derivatives as glutamate receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05013233A true MXPA05013233A (es) | 2006-03-09 |
Family
ID=33495606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05013233A MXPA05013233A (es) | 2003-06-12 | 2004-06-07 | Derivados de imidazol heteroaril-substituidos como antagonistas del receptor de glutamato. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7241760B2 (es) |
| EP (1) | EP1670784B1 (es) |
| JP (1) | JP4395512B2 (es) |
| KR (1) | KR100717914B1 (es) |
| CN (1) | CN100462363C (es) |
| AR (1) | AR044657A1 (es) |
| AT (1) | ATE495168T1 (es) |
| AU (1) | AU2004247368B2 (es) |
| BR (1) | BRPI0411350A (es) |
| CA (1) | CA2527587C (es) |
| CL (1) | CL2004001430A1 (es) |
| CO (1) | CO5660263A2 (es) |
| DE (1) | DE602004031030D1 (es) |
| ES (1) | ES2358512T3 (es) |
| HK (1) | HK1093071A1 (es) |
| IL (1) | IL172080A (es) |
| MX (1) | MXPA05013233A (es) |
| MY (1) | MY140206A (es) |
| NO (1) | NO332175B1 (es) |
| NZ (1) | NZ543638A (es) |
| RU (1) | RU2327697C2 (es) |
| TW (1) | TWI336700B (es) |
| WO (1) | WO2004111040A1 (es) |
| ZA (1) | ZA200509908B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7452909B2 (en) * | 2003-09-04 | 2008-11-18 | Hoffman-La Roche Inc. | Imidazole derivatives |
| ES2339477T3 (es) | 2005-03-23 | 2010-05-20 | F.Hoffmann-La Roche Ag | Derivados de acetilenil-pirazolo-pirimidina como antagonistas de mglur2. |
| WO2007039439A1 (en) | 2005-09-27 | 2007-04-12 | F.Hoffmann-La Roche Ag | Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists |
| DE102006011574A1 (de) * | 2006-03-10 | 2007-10-31 | Grünenthal GmbH | Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln |
| WO2009024491A1 (en) * | 2007-08-20 | 2009-02-26 | F. Hoffmann-La Roche Ag | Use of mglur5 antagonists for the treatment of gerd |
| US8334287B2 (en) * | 2009-07-17 | 2012-12-18 | Hoffmann-La Roche Inc. | Imidazoles |
| US9447099B2 (en) | 2011-10-04 | 2016-09-20 | Hoffmann-La Roche Inc. | Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine |
| CN114746408A (zh) * | 2019-12-02 | 2022-07-12 | 豪夫迈·罗氏有限公司 | 炔基-(杂芳基)-甲酰胺hcn1抑制剂 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5354867A (en) * | 1988-12-06 | 1994-10-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
| TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| US6774138B2 (en) * | 1999-08-31 | 2004-08-10 | Merck & Co., Inc. | Thiazolyl(pyridyl)ethyne compounds |
| CA2383524C (en) * | 1999-08-31 | 2010-09-28 | Merck & Co., Inc. | Thiazolyl alkynyl compounds and methods of use thereof |
| AU2001273574A1 (en) * | 2000-07-24 | 2002-02-05 | Krenitsky Pharmaceuticals Inc. | Substituted 5-alkynyl pyrimidines having neurotrophic activity |
| DE10040683C2 (de) * | 2000-08-19 | 2002-06-27 | Hinderer & Muehlich Kg | Verfahren zum Positionieren einer Patrize an einer Gegendruckwalze einer Prägestation |
| DK1349839T3 (da) * | 2000-12-04 | 2005-06-06 | Hoffmann La Roche | Phenylethenyl- eller phenylethinylderivater som glutamatraceptorantagonister |
-
2004
- 2004-06-07 WO PCT/EP2004/006111 patent/WO2004111040A1/en active IP Right Grant
- 2004-06-07 AU AU2004247368A patent/AU2004247368B2/en not_active Ceased
- 2004-06-07 CA CA2527587A patent/CA2527587C/en not_active Expired - Fee Related
- 2004-06-07 JP JP2006515286A patent/JP4395512B2/ja not_active Expired - Fee Related
- 2004-06-07 RU RU2006100106/04A patent/RU2327697C2/ru not_active IP Right Cessation
- 2004-06-07 NZ NZ543638A patent/NZ543638A/en not_active IP Right Cessation
- 2004-06-07 EP EP04739649A patent/EP1670784B1/en not_active Expired - Lifetime
- 2004-06-07 KR KR1020057023885A patent/KR100717914B1/ko not_active IP Right Cessation
- 2004-06-07 MX MXPA05013233A patent/MXPA05013233A/es active IP Right Grant
- 2004-06-07 CN CNB2004800158698A patent/CN100462363C/zh not_active Expired - Fee Related
- 2004-06-07 DE DE602004031030T patent/DE602004031030D1/de not_active Expired - Lifetime
- 2004-06-07 AT AT04739649T patent/ATE495168T1/de active
- 2004-06-07 ES ES04739649T patent/ES2358512T3/es not_active Expired - Lifetime
- 2004-06-07 BR BRPI0411350-0A patent/BRPI0411350A/pt not_active IP Right Cessation
- 2004-06-09 CL CL200401430A patent/CL2004001430A1/es unknown
- 2004-06-09 TW TW093116555A patent/TWI336700B/zh not_active IP Right Cessation
- 2004-06-10 AR ARP040102004A patent/AR044657A1/es active IP Right Grant
- 2004-06-10 MY MYPI20042241A patent/MY140206A/en unknown
- 2004-06-12 US US10/866,255 patent/US7241760B2/en not_active Expired - Fee Related
-
2005
- 2005-11-21 IL IL172080A patent/IL172080A/en not_active IP Right Cessation
- 2005-12-05 NO NO20055758A patent/NO332175B1/no not_active IP Right Cessation
- 2005-12-05 CO CO05123374A patent/CO5660263A2/es active IP Right Grant
- 2005-12-06 ZA ZA200509908A patent/ZA200509908B/xx unknown
-
2006
- 2006-12-18 HK HK06113875.7A patent/HK1093071A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS20050195A (en) | Heterocyclic substituted piperazines for the treatment of schizophrenia | |
| ATE384050T1 (de) | Benzazepinderivate als histamin-h3-antagonisten | |
| TW200531689A (en) | Therapeutic agents | |
| DE602004022668D1 (de) | 5-gliedrige heterocyclische p-38 inhibitoren | |
| TW200504034A (en) | Therapeutic agents | |
| AU2003242544A1 (en) | New indolylpiperidine derivatives as potent antihistaminic and antiallergic agents | |
| UA92503C2 (ru) | Соединения 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенного пиридина для лечения неврологических, психиатрических или болевых расстройств | |
| NO20064238L (no) | Imidazolinderivater med CB1 agonistlsk aktivitet | |
| TW200635903A (en) | Therapeutic agents | |
| RS20050892A (en) | Imidazole derivatives as glutamate receptor antagonists | |
| NO20080563L (no) | Pyrazol[3,4-d]azepinderivater som histamin H3 antagonister | |
| TW200509933A (en) | Therapeutic agents | |
| TW200633986A (en) | Therapeutic agents | |
| MX2008002065A (es) | Derivados de pirazola como agentes terapeuticos. | |
| NO20060112L (no) | Imidazolderivater III | |
| TW200519101A (en) | Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors | |
| MXPA05004273A (es) | Derivados de fenilalquil y piridilalquil piperazina. | |
| MXPA05013233A (es) | Derivados de imidazol heteroaril-substituidos como antagonistas del receptor de glutamato. | |
| MXPA05011163A (es) | Derivados de 3-benzhidriliden-8-azabiciclo[3.2.1]octano con actividad de receptores opioides. | |
| AU2003226765A8 (en) | Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents | |
| TW200519102A (en) | Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors | |
| DE502004007387D1 (de) | Triazolverbindungen und ihre therapeutische verwendung | |
| NO20055997L (no) | Diarylmetylidenpiperidinderivater og deres anvendelse som opiodreseptoragonister | |
| DK1373218T3 (da) | Imidazolylderivater til anvendelse som histamin H3-receptorligander | |
| GB0311349D0 (en) | Therapeutic agents, compositions, preparations and uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |